Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02871791 · ClinicalTrials.gov registry record · Phase 1
Palbociclib With Everolimus + Exemestane In BC
A Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 1
- Study location
NCT02871791: Completed Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer, sponsored by Dana-Farber Cancer Institute.
NCT02871791 is a Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 41 participants, below the 156-participant average among 3 other Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02871791, a Phase 1 study of Human Epidermal Growth Factor 2 Negative Carcinoma of Breast and Hormone Receptor (HR)-Positive Breast Cancer, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * Palbociclib * Everolimus * Exemestane
Primary Outcome
CBR is defined as the proportion of participants achieving complete response, partial response or stable disease for more than 6 months (CR+PR+SD ≥ 24 weeks) taking as reference the smallest measurements recorded since the treatment started, including the baseline measurements.
Conditions Studied
Interventions
- DRUG Exemestane
- DRUG Everolimus
- DRUG Palbociclib
Study Locations (1)
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-08-24 |
| Est. Completion | 2021-09 |
| Phase | Phase 1 |
What the finished NCT02871791 record still lists
NCT02871791 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 156-participant average among 3 other Human Epidermal Growth Factor 2 Negative Carcinoma of Breast trials with a reported enrollment target (74% lower).
The record links to 2 conditions, with Human Epidermal Growth Factor 2 Negative Carcinoma of Breast appearing as the primary indexed condition, and to 3 interventions - of which Exemestane is the first listed.
NCT02871791 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02871791 about?
NCT02871791 is a clinical study titled "Palbociclib With Everolimus + Exemestane In BC". This research study is studying a combination of targeted therapy and hormonal therapy as a possible treatment for breast cancer that has spread to other places in the body and is hormone receptor positive (HR+) and HER2-negative. The names of the study interventions involved in this study are: * ...
What is the current status of trial NCT02871791?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-08-24. Estimated completion is 2021-09.
What conditions does trial NCT02871791 study?
This clinical trial studies the following conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor (HR)-Positive Breast Cancer.
What interventions are being tested in trial NCT02871791?
The interventions under investigation include: Exemestane (DRUG), Everolimus (DRUG), Palbociclib (DRUG).
Who is sponsoring clinical trial NCT02871791?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02871791 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
RECRUITING · Phase 1
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI